Laurence J, Haller HM, Mannucci PM, Nangaku M, Praga M. Rodriguez de Córdoba S: Atypical hemolytic uremic syndrome (aHUS): essential aspects of an acute diagnosis. Clin Adv Hematol Oncol. 2016;14 Suppl 11(11):2–15.
Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey M, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554–62.
Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, et al. Complement genes strongly predicht recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663–75.
Fakhouri F, Hourmant M, Campistol J, Cataland S, Espinosa M, Gaber A, Menne J, Minetti E, Provot F, Rondeau E, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84–93.
Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petiprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, et al. Use of higly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2019;30(12):2449–63.
Sheridan D, Yu Z, Zhang Y, Patel R, Sun F, Lasaro M, Bouchard K, Andrien B, Marozsan A, Wang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13(4):e0195909.
Yang D, Giragossian C, Castellano S, Lasaro M, Xiao H, Saraf H, Hess Kenny C, Rybina I, Huang Z, Ahlberg J, et al. Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn. MAbs. 2017;9(7):1105–17.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 2020;97(6):1287–96.
Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon S, et al. Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep. 2021;6(6):1603–13.
Tomazos I, Hatswell A, Cataland S, Chen P, Freemantle N, Lommele A, Deighton K, Knowles E, Sheerin N, Rondeau E. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clincal trial data. Clin Nephrol. 2022;97(5):261–72.
Vu T, Ortiz S, Katsuno M, Annane D, Mantegazza R, Beasley K, Aguzzi R, Howard J Jr. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J Neurol. 2023;270(6):3129–37.
Howard J Jr, Utsugisawa K, Benatar M, Murai H, Barohn R, Illa I, Jacob S, Vissing J, Burns T, Kissel J, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–86.
Monteleone J, Gao X, Kleijn H, Bellanti F, Pelto R. Eculizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. Front Neurol. 2021;12: 696385.
Ultomiris prescribing information. https://ec.europa.eu/health/documents/community-register/2020/20200625148516/anx_148516_de.pdf. Accessed 1 Jan 2024.
Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–59.
Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommelé A, Kupelian V, Gasteyger C, Greenbaum L, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408–18.
Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol. 2021;17(8):543–53.
Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc A, Ville S, Pouteil-Noble C, Coindre J, Le Quintrec M, Rondeau E, et al. Eculizumab discontinuation in children and adults with atypical haemolytic uremic syndrome: a prospective multicentric study. Blood. 2021;137(18):2438–49.
Olson S, Lu E, Sulpizio E, Shatzel J, Rueda J, DeLoughery T. When to stop eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol. 2018;48(2):96–107.
Laurence J. Defining treatment duratin in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach. Clin Adv Hematol Oncol. 2020;18(4):221–30.
Menne J, Delmas Y, Fakhouri F, Licht C, Lommelé A, Minetti E, Provot F, Rondeau E, Sheerin N, Wang J, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019;20(1):125.
Avila A, Cao M, Espinosa M, Manrique J, Morales E. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med. 2023;10:1264310.
Tanaka K, Adams B, Aris A, Fujita N, Ogawa M, Ortiz S, Vallee M, Greenbaum L. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021;36(4):889–98.
Hayes W, Tschumi S, Ling S, Feber J, Kirschfink M. LIcht C: Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol. 2015;30(5):775–81.
Oruc A, Ayar Y, Vuruskan B, Yildiz A, Aktas N, Yavuz M, Gullulu M, Dilek K, Ersoy A. Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome. Nefrologia (Engl Ed). 2018;38(4):448–50.
Rabia K, Faruk T, Furkan S, Lazrak E, Ozen P, Tuncer A. Probable eculizumab-associanted hepatotoxicity in a patient with neuromyelitis optica: a case report. Int J Neurosci. 2023;31:1–5.
Benamu E, Montoya J. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29(4):319–29.
Gäckler A, Kaulfuß M, Rohn H, Vogel U, Claus H, Feldkamp T, Kribben A, Witzke O. Failure of first menigococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrol Dial Transplant. 2018;35(2):298–303.
Fam S, Werneburg B, Pandya S, Parks B, Mashhoon Y, Allen K, Frick G, Beasley K, Zodiatis A, Chitikireddi V, et al. Clinical and real-world pharmacovigilance data of meningococcal infections in eculizumab- or ravulizumab-treated patients (EPO-260). Eur J Neurol. 2023;30(Suppl. 1):490.
Willrich M, Ladwig P, Martinez M, Sridharan M, Go R, Murray D. Monitoring ravulizumab effect on complement assays. J Immunol Methods. 2021;490: 112944.
Cataland S, Ariceta G, Chen P, Dixon B. garlo K, Greenbaum L, Rondeau E, Scully M, Ortiz S: Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab. Blood. 2019;134(Supplement 1):1099.
Jehn U, Altuner U, Pavenstädt H, Reuter S. First report on successful conversion of long-term treatment of recurrent atypical hemolytic uremic syndrome with eculizumab to ravulizumab in a renal transplant patient. Transplant Int. 2022;35:10846.
Schaefer F, Al-Dakkak I, Anokhina E, Cohen D, Greenbaum L, Ariceta M. Chracteristics and outcome of patients with atypical hemolytic uremic syndrome switching to ravulizumab from eculizumab: a global registry analysis. J Am Soc Nephrol. 2023;34:987.
Richter A, Anton S, Koch P, Dennett S. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25(8):2307–35.
Jang J, Gomez R, Bumbea H, Nogaieva L, Wong L, Lim S, Kim Y, Park J. A phase III, radomised, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria. EJHaem. 2022;4(1):26–36.
Levy A, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Med Econ. 2022;25(1):249–59.
- The Renal Warrior Project. Join Now
- Source: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03638-3